Literature DB >> 21917057

Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age.

Lin Lin1, Jian-Wei Zhang, Yue Huang, Jie Bai, Mei-Hua Cai, Ma-Zhong Zhang.   

Abstract

BACKGROUND: Information has been very limited on the population pharmacokinetics (PK) of etomidate in pediatric patients. The purpose of this study was to characterize the PK of etomidate in children.
METHODS: Forty-nine children aged over 6 months undergoing elective surgery received etomidate 0.3 mg·kg(-1) bolus i.v. within 15 s for anesthesia induction. Arterial blood samples were collected for 2 h after injection. A population nonlinear mixed effects modeling approach was used to characterize etomidate PK. Estimates were standardized to a 70-kg adult using allometric size models.
RESULTS: Children had a median age of 4 years (0.53-13.21 years) and weight 15.7 kg (7.5-52 kg). PK of etomidate was best estimated using a three-compartment model with weight on systemic (Cl(1)) and inter-compartmental clearances (Cl(2), Cl(3)), central (V(1)), and peripheral compartment volumes (V(2), V(3)). The most significant PK covariate was age, with increasing age having reduced size-adjusted Cl(1), V(1), and V(3) (all P < 0.01). The estimates of PK parameter (standardized to 70-kg adult) for a typical 4-year-old children were Cl(1) = 1.50 l·min(-1), Cl(2) = 1.95 l·min(-1), Cl(3) = 1.23 l·min(-1), V(1) = 9.51 l, V(2) = 11.0 l, and V(3) = 79.2 l, respectively.
CONCLUSIONS: Owing to enhanced clearance and increased central compartment volume of etomidate, smaller (younger) children will require higher etomidate bolus dose than larger (older) children to achieve equivalent plasma concentrations. The dependence of Cl(1) and V(1) on age does not support weight-based etomidate dosing in smaller children.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917057     DOI: 10.1111/j.1460-9592.2011.03696.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  7 in total

1.  A reduction in between subject variability is not mandatory for selecting a new covariate.

Authors:  Chakradhar V Lagishetty; Pavan Vajjah; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-06       Impact factor: 2.745

2.  Continuous-Infusion Etomidate in a Patient Receiving Extracorporeal Membrane Oxygenation.

Authors:  Joseph M LaRochelle; Bonnie Desselle; Janet L Rossi
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

3.  Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease.

Authors:  Felice Su; Mohammed H El-Komy; Gregory B Hammer; Adam Frymoyer; Carol A Cohane; David R Drover
Journal:  Biopharm Drug Dispos       Date:  2015-01-21       Impact factor: 1.627

Review 4.  Advances in pediatric pharmacology, therapeutics, and toxicology.

Authors:  Daniel Gonzalez; Ian M Paul; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Adv Pediatr       Date:  2014-05-06

Review 5.  Etomidate in pediatric anesthesiology: Where are we now?

Authors:  Joseph D Tobias
Journal:  Saudi J Anaesth       Date:  2015 Oct-Dec

6.  Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones.

Authors:  Hongbin Gu; Mazhong Zhang; Meihua Cai; Jinfen Liu
Journal:  Med Sci Monit       Date:  2015-11-16

Review 7.  Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics.

Authors:  Beatrijs I Valk; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2021-06-01       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.